Skip to main content
SpringerLink
Log in

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scarmeas N, Brandt J, Albert M, et al.: Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005, 62:1601–1608.

    Article  PubMed  Google Scholar 

  2. Ballard C, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006: CD003476.

  3. Katz I, de Deyn PP, Mintzer J, et al.: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebocontrolled clinical trials. Int J Geriatr Psychiatry 2007, 22:475–484.

    Article  PubMed  Google Scholar 

  4. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006, 14:191–210.

    Article  PubMed  Google Scholar 

  5. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005, 294:1934–1943.

    Article  PubMed  CAS  Google Scholar 

  6. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189–198.

    Article  PubMed  CAS  Google Scholar 

  7. Wang PS, Schneeweiss S, Avorn J, et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335–2341.

    Article  PubMed  CAS  Google Scholar 

  8. Shea C, MacKnight C, Rockwood K: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998, 10:229–238.

    Article  PubMed  CAS  Google Scholar 

  9. Cummings JL, Knopman D: Advances in the treatment of behavioral disturbances in Alzheimer’s disease. Neurology 1999, 53:899–901.

    PubMed  CAS  Google Scholar 

  10. Kurlan R, Cummings J, Raman R, Thal L: Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007, 68:1356–1363.

    Article  PubMed  CAS  Google Scholar 

  11. Olin JT, Fox LS, Pawluczyk S, et al.: A pilot randomized trial of carbamazepine for behavioral symptoms in treatmentresistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001, 9:400–405.

    Article  PubMed  CAS  Google Scholar 

  12. Lonergan ET, Cameron M, Luxenberg J: Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004: CD003945.

  13. Teri L, Logsdon RG, Peskind E, et al.: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000, 55:1271–1278.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Karen Marder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marder, K. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. Curr Neurol Neurosci Rep 7, 363–365 (2007). https://doi.org/10.1007/s11910-007-0056-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-007-0056-9

Keywords

Search

Navigation